Beyond the limits of oxygen: effects of hypoxia in a hormone-independent prostate cancer cell line by Mamede, Ana Catarina Manjolinha et al.
Hindawi Publishing Corporation
ISRN Oncology
Volume 2013, Article ID 918207, 8 pages
http://dx.doi.org/10.1155/2013/918207
Research Article
Beyond the Limits of Oxygen: Effects of Hypoxia in
a Hormone-Independent Prostate Cancer Cell Line
A. C. Mamede,1,2,3 A. M. Abrantes,1,3 L. Pedrosa,1,4 J. E. Casalta-Lopes,1 A. S. Pires,1,4
R. J. Teixo,1,4 A. C. Gonçalves,3,5 A. B. Sarmento-Ribeiro,3,5 C. J. Maia,2 and M. F. Botelho1,3
1 Biophysics Unit, Institute of Biomedical Research on Light and Image (IBILI), Faculty of Medicine,
University of Coimbra, Azinhaga de Santa Comba, Celas, 3000-548 Coimbra, Portugal
2 CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal
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Prostate cancer (PCa) has a high incidence worldwide. One of the major causes of PCa resistance is intratumoral hypoxia. In
solid tumors, hypoxia is strongly associated with malignant progression and resistance to therapy, which is an indicator of poor
prognosis.The antiproliferative effect and induced death caused by doxorubicin, epirubicin, cisplatin, and flutamide in a hormone-
independent PCa cell line will be evaluated. The hypoxia effect on drug resistance to these drugs, as well as cell proliferation and
migration, will be also analyzed. All drugs induced an antiproliferative effect and also cell death in the cell line under study. Hypoxia
made the cells more resistant to all drugs. Moreover, our results reveal that long time cell exposure to hypoxia decreases cellular
proliferation and migration. Hypoxia can influence cellular resistance, proliferation, and migration. This study shows that hypoxia
may be a key factor in the regulation of PCa.
1. Introduction
Prostate cancer (PCa) is one of the most common diseases
in the world, being the sixth leading cause of cancer death
worldwide [1].The incidence of PCa varies according to three
major risk factors: age, ethnicity, and familial predisposition
[2–6].
Hypoxia can be defined as a reduction in oxygen partial
pressure (pO
2
). This characteristic constitutes a condition of
various pathophysiological states such as ischemic vascular
disease, myocardial infarction, stroke, respiratory insuffi-
ciency, and cancer [7]. Clinically relevant levels of hypoxia
are detected in 50% to 60% of solid tumors [8]. Hypoxia
results from an imbalance between rate of consumption and
supply of oxygen to cancer cells, thus compromising several
cellular functions. Cancer cells have the capacity to adapt to
hypoxic environments due to various genetic and epigenetic
mechanisms and alterations at cellular level that contribute to
adaptive changes which lead to a clinically aggressive pheno-
type, having hypoxic tumors a poor prognosis. These tumors
are more difficult to treat, being highly resistant, presenting
an increased risk of recurrence and progression [9, 10].
Regarding PCa, intratumoral oxygen levels were evalu-
ated through a polarographic electrode with the form of a
needle, and it was found that pO
2
in PCa was significantly
lower (pO
2
= 2.4mmHg) than in normal tissues (muscle, pO
2
= 30mmHg) [11]. In fact, increase of hypoxia may be critical
in PCa progression and resistance [12].
In thiswork, we aim at studying the antiproliferative effect
and cell death induced by various agents of chemotherapy and
hormonal therapy in a human hormone-independent PCa
cell line. Response to these treatment agents will be evaluated
in normoxia and hypoxia conditions. Chemotherapy is a
treatment used in PCa when it stops responding to hormone
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Table 1: Drugs concentration (𝜇M) for flow cytometry studies.
𝐶1 (𝜇M) 𝐶2 (𝜇M) 𝐶3 (𝜇M)
Doxorubicin 0.0025 1.69 25
Epirubicin 0.025 1.11 5
Cisplatin 0.75 15.31 75
Flutamide 5 64 500
therapy. However, several studies show that some antiandro-
gens can have an inhibitory effect, independent of androgen
receptor expression, in advanced PCa. Cellular proliferation
and migration of the cell line under study will be determined
under normoxia and hypoxia environments.
2. Methods
2.1. Cell Culture. Humanhormone-independent PCa cell line
(PC3), acquired from American Type Culture Collection
(Rockville, MD, USA), was cultured in RPMI-1640 (Sigma
R4130) supplemented with 100𝜇M sodium pyruvate (Gibco
11360), 10% fetal bovine serum (Sigma F7524), and 1% antibi-
otic/antimycotic (Gibco 15140-122). Cells were maintained at
37∘C and 5% CO
2
in a cell incubator (Heraeus HeraCell 150
CO
2
Incubator—BridgePath Scientific, MD, USA).
2.2. Evaluation of Antiproliferative Effect Induced by Chemo-
therapy and Hormonal Therapy. Chemotherapy agents (dox-
orubicin, epirubicin, and cisplatin), as well as an antiandro-
gen (flutamide), were used. In this study, cells were incubated
with different concentrations of these drugs. After 24, 48, 72,
and 96 h of drug stimulation, cell proliferation was evaluated
by the colorimetric test MTT (3-(4,5-dimethylthiazol-2)2,5-
diphenyltetrazolium bromide), as previously described by
Mamede et al. [13]. The obtained results were analyzed and
processed in software OriginPro 8.0, being the cytotoxicity
expressed as a percentage of inhibition of cell proliferation
when compared to control experiments. This allows the
determination of the concentration that inhibits cell prolif-
eration in 50% (IC
50
) through a sigmoid fitting (Boltzmann
function).
2.3. Characterization of Cell Death Induced by Chemotherapy
and Hormonal Therapy. Cells were incubated with three
concentrations of the drugs for 48 h (Table 1). The first con-
centration (𝐶1) corresponds to a drug concentration that
does not inhibit cell proliferation, the second concentration
(𝐶2) corresponds to IC
50
and, finally, the third concentration
(𝐶3) corresponds to a concentration that totally inhibits
cell proliferation (values based on dose-response curves
obtained for each drug after 48 h of incubation). Annexin-
V/propidium iodide (AV/PI) incorporation assay was used,
as already described by Abrantes et al. [14].
2.4. Normoxia versus Hypoxia. The following studies were









, and 5% CO
2
) conditions. Studies in
hypoxia were performed in a controlled environment cham-
ber (Plas-Labs, Lansing, MI).
2.5. Evaluation of Cellular Resistance to Chemotherapy and
Hormonal Therapy in Hypoxia. Cells were incubated with
IC
50
determined in normoxia for each drug. These experi-
ments were performed during 48 h in hypoxia and normoxia
conditions. After 48 h, cells were submitted to MTT prolifer-
ation assay.
2.6. Evaluation of Cell Proliferation inHypoxia. Acell suspen-
sion of 70000 cells/mLwas distributed in 12-well-plates. After
24 h, cells were placed in hypoxia and normoxia. The cells in
normoxia conditions were considered as controls. After 48 h,
mitochondrial activity was assessed byMTT assay, according
to the procedure described above, and protein synthesis was
evaluated through the sulforhodamine B (SRB) assay accord-
ing to Houghton et al. [15]. SRB is an anionic purple dye that
binds to proteins through electrostatic bonds. The fixed dye
can be measured by spectrophotometry after solubilization,
which correlates with the rate of total protein synthesis. The
contents of each well were transferred to a plate with 96
wells, and the absorbance was quantified at 540 nm with a
reference filter of 690 nm in an ELISA spectrophotometer
(SLT Spectra).
2.7. Evaluation of Cell Migration in Hypoxia. Scratch assay is
commonly used to evaluate cell migration in vitro, according
to Liang et al. [16]. In this study, cells were plated in Petri
dishes. When the cellular confluence reached 90%, a risk
was drawn using a tip in order to separate the monolayer.
Immediately after (0 h) and at regular intervals of time (8 and
24 h), images were captured (100x). Cells were photographed
with a microscope Motic AE31 through the system Motic
Images Advanced 3.2. Images were compared in order to
quantify the rate of closure by (1), where 𝐴
0
is the initial area
of risk (when 𝑡 = 0 h), 𝐴
𝑡
corresponds to risk area at time 𝑡
(when 𝑡 = 8 h or 𝑡 = 24 h), and 𝑇 is time in hours. This test
was conducted in hypoxia and normoxia conditions, and rate
of risk closure in both conditions and its standard deviation
were calculated







2.8. Statistical Analysis. Statistical analysis was performed
using IBM SPSS v.19 software. In the descriptive analysis,
measures of central tendency (mean andmedian) and disper-
sion (standard deviation and interquartile range) for quan-
titative variables were determined. The normal distribution
of these variables was assessed using the Shapiro-Wilk test.
In the case of normal underlying distributions, parametric
tests were used tomake comparisons, and in the opposite case
we used nonparametric tests. The comparison of quantitative
variables between two groups was performed using Student
t test (parametric) and Mann-Whitney test (nonparametric).
Comparison of quantitative variables in more than two
groups was obtained using one-factor ANOVA test with post
hoc analysis using the Tuckey test (parametric tests) and the
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Figure 1: Dose-response curves resulting from incubation of PC3 cell linewith doxorubicin (a), epirubicin (b), cisplatin (c), and flutamide (d).
Each experiment was performed in duplicate and repeated in three different sets of tests.
Kruskal-Wallis test, with multiple comparisons performed
using the Mann-Whitney test with Bonferroni correction. It
was considered a significance level of 5%.
3. Results
Pharmacological response of PC3 cell line to doxorubicin,
epirubicin, cisplatin, and flutamide for incubation times of
24, 48, 72, and 96 h were shown at Figures 1(a), 1(b), 1(c), and
1(d).
Cell proliferation decreases with increasing drug con-
centration and incubation period, except for doxorubicin,
epirubicin, and cisplatin at 96 h, in which there is a significant
increase (𝑃 < 0.05) compared to 72 h (Table 2). Incubation
with doxorubicin and epirubicin resulted in similar IC
50
val-
ues over time. It is worth noting that the proliferation was
more easily inhibited with doxorubicin and epirubicin than
with cisplatin or flutamide.
After cell proliferation, the identification of cell death was
performed by flow cytometry using the double staining AV/
PI. The results showed that as the concentration of drugs
increases, the number of viable cells decreases in a dose-
dependentmanner, as shown in Figure 2. Cell death increases
in response to increasing doxorubicin concentration. Cell
death occurred at all concentrations predominantly by necro-
sis, as observed in Figure 2(a). By IC
50
(1.69 03BCM) the
cell death was 27%. Regarding the results obtained after cell
















































































Figure 2: Cell viability analyzed by flowcytometry using double stainingwithAV/PI. Schematic representation of the percentage of viable cells
(VC), in initial apoptosis (EAC), in late apoptosis/necrosis (LAC/NC), and necrosis (NC) after incubation with doxorubicin (a), epirubicin
(b), cisplatin (c), and flutamide (d). Data express the mean and standard deviation of three independent experiments.
also increases in response to increase of drug concentration
(Figure 2(b)). At the lowest epirubicin concentration the cell
death occurred predominantly by initial apoptosis (14%),
which was statistically significant when compared to control
(𝑃 < 0.05). However, at the highest concentration used
(5 𝜇M), cell death occurred mainly through necrosis. With
the IC
50
(1.11 𝜇M), the viability only reached 11%.
The cell death increased by increasing cisplatin concen-
tration (Figure 2(c)). At IC
50
(15.31 𝜇M), cell death occurred
predominantly by initial (27%) and late (30%) apoptosis.
Like the IC
50
, also with the higher concentration (75𝜇M)
there is a predominance of cell death by initial (30%) and
late (31%) apoptosis. These results were significantly different
from control (𝑃 < 0.05). Cell viability decreases by increasing
flutamide concentration, as shown in Figure 2(d) (no signifi-
cant differences between concentrations were obtained). The
cell death induced by flutamide did not exceed 50%.
A ratio between proliferation in hypoxia and normoxia
conditions was calculated in order to analyze cell drug resis-
tance in hypoxia (Figure 3). Flutamide had the lowest ratio
between hypoxia/normoxia (H/N = 1.34), whereas epiru-
bicin had a significantly higher ratio H/N = 1.87 (𝑃 = 0.032).
The results concerning the analysis of cell proliferation in
hypoxia and normoxia throughMTT and SRB assays showed
that there is a decrease in cell proliferation in hypoxia. As
shown in Figure 4, the results obtained by MTT and SRB
assays are similar. However, in hypoxia there was a decrease
of 68% and 64% of cell proliferation through MTT and SRB,
respectively.
Scratch assay revealed that there was a decrease in the
risk area over time, as observed in Figure 5. After 8 h, we
still observed no differences in migration between the two
conditions, being however a visible decreased risk area as
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Figure 3: Cellular resistance to treatment with chemotherapy (cis-
platin, doxorubicin, and epirubicin) and hormonal therapy (flutam-
ide). The results are expressed as the ratio between the calculated
proliferation in hypoxia and normoxia and represent the mean and
standard deviation of six independent experiments.





















Figure 4: Cell proliferation in hypoxia, determined by MTT and
SRB assay, relatives to normoxia and its standard deviation. The
results represent the mean and standard deviation of six indepen-
dent experiments.
24 h, the risk in normoxia is completely closed (Figure 5(c)),
but not in hypoxia condition (Figure 5(f)).
Regarding the closure risk rate, there was a decrease in
this value over time, being higher in normoxia than in hyp-
oxia (Table 3).
4. Discussion
With hypoxia being strongly associated with malignant pro-
gression and resistance, this condition becomes a central
issue in cancer treatment [12]. For this reason, it is important
to study the effect of hypoxia in PCa, particularly learning
about the influence of this microenvironment in cell resis-
tance, proliferation, and migration.
Table 2: IC50 (𝜇M) obtained for PC3 cell line after incubation with
doxorubicin, epirubicin, cisplatin, and flutamide at 24, 48, 72, and
96 hours of exposure. 𝑅2 is also indicated.






















































Table 3: Rate of closure risk in normoxia and hypoxia and its stan-
dard deviation. The results represent the average of three indepen-
dent experiments.
Normoxia (MED ± SD) Hypoxia (MED ± SD)
Time (h) 8 5.65 ± 2.30 2.1 ± 1.45
24 3.51 ± 2.34 1.5 ± 0.93
In PCa treatment, hormonal therapy has particular
importance. When PCa cells are androgen dependent, it is
important to use therapeutic strategies that are based on
inhibition of androgen receptor (AR) using antagonists of
AR, such as flutamide [17].When PCa cells become hormone
resistant, hormonal therapy becomes ineffective, and it is
necessary to use, for example, conventional chemotherapy.
Taking into account that this form of treatment is largely
palliative and not curative, chemotherapy is still subject of
study in this type of cancer, being not used as the first choice
in PCa treatment [18].
ThroughMTT results, it can be concluded that therewas a
decrease in the IC
50
values over time with all drugs, However,
there was a significant increase (𝑃 < 0.05) in IC
50
value at
96 h compared to 72 h after cell incubation with doxorubicin,
epirubicin, or cisplatin. This may be due to the acquisition of
cellular chemoresistance over time. Cells are more sensitive
to doxorubicin and epirubicin than cisplatin. Smith et al.
[19] conducted studies in another PCa cell line (LNCaP),
which is AR positive, and concluded that cisplatin treatment
enhances the expression of metallothioneins, molecules that
induce drug resistance. Metallothioneins are a family of
proteins which play a role in resistance to chemotherapy
and radiotherapy.Their expression is upregulated in response
to presence of metal ions, such as zinc, which is highly
concentrated in prostatic tissue [19]. The resistance to cis-
platin may be related to the expression of the protein zinc-
finger protein 143 (ZNF143), which is induced by treatment




Figure 5: Cell migration at 0 ((a) and (d)), 8 ((b) and (e)), and 24 hours ((c) and (f)) in normoxia ((a), (b), and (c)) and hypoxia ((d), (e),
and (f)). Cells were photographed through an optical microscope at a magnification of 100x.
the PC3 resistance to cisplatin and demonstrated that ZNF143
protein is overexpressed in cells resistant to cisplatin, since
it found that inhibition of ZNF143 increased the cisplatin
sensitivity of PC3. Although PC3 does not express AR, it
has been demonstrated that flutamide inhibits proliferation
of AR negative PCa cells [21–23]. However, this mechanism
of inhibition remains to be elucidated.
Through flow cytometry studies, it was observed that
doxorubicin IC
50
incubation results in a 73% of cell viability,
while epirubicin incubation results in a much lower viability.
In addition, our results suggest that doxorubicin only inhibits
cellular proliferation, while epirubicin inhibits cellular pro-
liferation and causes cell death. Regarding the cell treatment
with flutamide, cell death did not exceed 50%, indicating that
flutamide inhibits cell proliferation but does not induce cell
death.
All assays in hypoxia were performed over a long period
of time (48 h), to better mimic the real tumor environment
where tumor vascularization is insufficient and oxygen dif-
fusion into the tissues is limited. It is well known that the
development of PCa is not only associatedwith increasing age
but also with increased hypoxia [24].
Our results show a great cellular resistance when cells
are incubated with epirubicin in hypoxic conditions but not
with cisplatin incubation. Flutamide has a lower H/N ratio
than all drugs used. Several studies corroborate the results
obtained in this work. Frederiksen et al. [25] showed that
PCa cells are resistant to doxorubicin in hypoxia probably
due to mutation or inactivation of P53 and overexpression
of Bcl-2. Other studies have demonstrated that Bcl-xL, an
antiapoptotic protein of the Bcl-2 family, is overexpressed in
PCa [26]. Frederiksen et al. [25] also claim that resistance to
anticancer drugs can be attributed in part to the increase of
multidrug resistance transporters, including P-glycoprotein
(PgP). In fact, PgP is upregulated in PC3 cells in response to
extracellular acidosis induced by hypoxia due to accumula-
tion of high lactate and low glucose concentration associated
with anaerobic glycolysis [27].
To investigate the influence of hypoxia on cell prolifer-
ation, MTT and SRB methods were used, which assess the
viability of the mitochondria and the rate of protein syn-
thesis, respectively. The results showed that cell proliferation
decreases in long hypoxia exposure, as confirmed by both
methodologies.
Scratch assay is based on the observation of cells in
confluent monolayer, that, being on the edge of the slot cre-
ated, moves to be close until cell-cell contacts are established
again. The results of cell migration can be correlated with
cell proliferation: in hypoxic environment there is a lower cell
migration, since after 24 h exposure to hypoxia, cells showed
no ability to migrate thereby “closing” the risk completely,
unlike what happened in normoxia. Thus, there was a
decrease not only in proliferation but also in cell migration.
Regarding the closure rate risk, there are a decrease over
time and also a decrease in hypoxia. Dai et al. [28] assessed
PC3migration during prolonged (>24 h) or short time (<6 h)
exposure to hypoxia and concluded that less exposure to
hypoxia results in a significant increase in cell migration,
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while longer exposure inhibited cell migration, a result that
corroborates the results obtained in this study. For more than
24 h exposure to hypoxia, these authors found an increase
in expression of genes involved in tumor invasion, including
matrixmetalloproteinase 2 (MMP-2) [29]. Studies performed
in vivowith lung cancer cells show that prolonged exposure to
hypoxia inhibits tumor progression in mice. Controversially,
the same study concluded that, under the same conditions,
tumor growth of human colorectal cancer was increased [30].
So, the authors concluded that mechanisms for response to
hypoxia depend on the cell type and exposure period.
Through this study it can be concluded that hypoxia is
a key factor in the regulation of PCa. Although this subject
is being increasingly studied, it is important to know more
about the influence of hypoxia in PCa, as well as on other
cancers, on order to develop better diagnosis and treatment
techniques.
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